Tech Company Financing Transactions
Xalud Therapeutics Funding Round
Xalud Therapeutics, operating out of New York, secured $30 million in funding from private investors.
Transaction Overview
Company Name
Announced On
8/25/2021
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors
Proceeds Purpose
Funds to support expansion of clinical development of its proprietary, non-viral gene therapy platform for multiple chronic inflammatory diseases
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
40 West 57th St. 1810
New York, NY 10019
USA
New York, NY 10019
USA
Phone
Website
Email Address
Overview
At Xalud Therapeutics, we are driven to discover, develop and provide novel treatments for chronic inflammatory diseases that can dramatically improve the health and quality of life for millions of suffering patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Diem Nguyen
Chief Marketing Officer
Steve Collins
Chief Operating Officer
Brendan O'Leary
Chief Technical Officer
Steve Vicik
VP - Bus. Development
Howard Rutman
VP - Regulatory Affairs
Kristin Murray
Browse more venture capital transactions:
Prev: 8/25/2021: Grafana Labs venture capital transaction
Next: 8/25/2021: Bridge to Life venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs